Cargando…

Thromboprophylaxis in Patients With Cancer and COVID-19

Detalles Bibliográficos
Autores principales:	Lecumberri, Ramón, Marcos-Jubilar, María, Guillén, Carolina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SEPAR. Published by Elsevier España, S.L.U. 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9452396/ https://www.ncbi.nlm.nih.gov/pubmed/36153216 http://dx.doi.org/10.1016/j.arbres.2022.08.006

Ejemplares similares

Immunothrombosis: Molecular Aspects and New Therapeutic Perspectives
por: Marcos-Jubilar, María, et al.
Publicado: (2023)

“Weighing” the risks and benefits – Thromboprophylaxis challenges in obese COVID-19 patients
por: Rokkam, Venkata Ram Pradeep, et al.
Publicado: (2020)

Pharmacological thromboprophylaxis and epidural anaesthesia
por: Harsoor, SS, et al.
Publicado: (2012)

Thromboprophylaxis strategies for COVID-19 patients
por: Porres-Aguilar, Mateo, et al.
Publicado: (2022)

Extended Thromboprophylaxis in Patients with COVID-19
por: Zhao, Wei, et al.
Publicado: (2021)

Heparin thromboprophylaxis in critically ill patients: Is it really changing outcome?
por: Gurjar, Mohan
Publicado: (2014)

Thromboprophylaxis Strategies for Hospitalized Patients With COVID-19
por: Porres-Aguilar, Mateo, et al.
Publicado: (2022)

Stroke and Thromboprophylaxis in the Era of COVID-19
por: Ma, Alice, et al.
Publicado: (2021)

Coagulation abnormalities & thromboprophylaxis in COVID-19
por: Jandial, Aditya, et al.
Publicado: (2021)

Thromboprophylaxis in COVID-19 – Rationale and considerations
por: Bristogiannis, Sotirios, et al.
Publicado: (2021)

Hospital-based use of thromboprophylaxis in patients with COVID-19
por: Spyropoulos, Alex C, et al.
Publicado: (2020)

Current thromboprophylaxis in urological cancer patients during COVID-19 pandemic
por: Ostrowski, Adam, et al.
Publicado: (2022)

Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients
por: Jonmarker, Sandra, et al.
Publicado: (2020)

Extended thromboprophylaxis with betrixaban: a new standard for acute medically ill patients
por: Cohen, Alexander T
Publicado: (2018)

ThromboprophylaXIs with Factor XI/XIa inhibitors for venous thromboembolism
por: Porres-Aguilar, Mateo
Publicado: (2023)

Pharmacologic therapeutic options for thromboprophylaxis in COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2020)

Thromboprophylaxis strategies to improve the prognosis of COVID-19
por: Bertoletti, Laurent, et al.
Publicado: (2021)

American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis
por: Cuker, Adam, et al.
Publicado: (2022)

Ethnic differences in thromboprophylaxis for COVID-19 patients: should they be considered?
por: Iba, Toshiaki, et al.
Publicado: (2021)

Enhanced thromboprophylaxis in critically ill patients with COVID-19 infection
por: Kummer, R.L., et al.
Publicado: (2021)

Intensified thromboprophylaxis in COVID-19 critically ill patients: Is it enough?
por: de Montmollin, Etienne, et al.
Publicado: (2021)

Thromboprophylaxis and anticoagulation for inpatients with COVID-19 in 2022 and beyond
por: Dalager-Pedersen, Michael
Publicado: (2022)

Thromboprophylaxis for children hospitalized with COVID‐19 and MIS‐C
por: Schmitz, Anna H., et al.
Publicado: (2022)

Thromboprophylaxis in COVID-19: Anti-FXa—the Missing Factor?
por: Dutt, Tina, et al.
Publicado: (2020)

The use of antiplatelet agents for arterial thromboprophylaxis in COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2021)

Thromboses and COVID-19: reducing inflammation in addition to thromboprophylaxis
por: Mehta, Puja, et al.
Publicado: (2021)

Thromboprophylaxis in Pregnant Women with COVID-19: An Unsolved Issue
por: Varlas, Valentin Nicolae, et al.
Publicado: (2023)

Incidence of Venous Thromboembolism in Hospitalized COVID-19 Patients Receiving Thromboprophylaxis
por: Huang, Jimmy, et al.
Publicado: (2022)

The Role of D-Dimer for Optimal Thromboprophylaxis Strategy in Patients with COVID-19
por: Bhoopat, Lantarima, et al.
Publicado: (2020)

Thromboprophylaxis in COVID‐19: Weight and severity adjusted intensified dosing
por: Engelen, Matthias M., et al.
Publicado: (2022)

Thromboprophylaxis: balancing evidence and experience during the COVID-19 pandemic
por: Marchandot, Benjamin, et al.
Publicado: (2020)

Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19
por: Rappaport, Stephen H., et al.
Publicado: (2020)

Thromboprophylaxis and clinical outcomes in moderate COVID-19 patients: A comparative study
por: Mohamed, Asmaa S., et al.
Publicado: (2022)

POST-discharge thromboprophylaxis in patients with COVID-19: a single-center experience
por: Simion, Chiara, et al.
Publicado: (2022)

Population pharmacokinetics of nadroparin for thromboprophylaxis in COVID‐19 intensive care unit patients
por: Romano, Lorenzo G. R., et al.
Publicado: (2022)

COVID-19: opening a new paradigm in thromboprophylaxis for critically ill patients?
por: Ferrandis, Raquel, et al.
Publicado: (2020)

Thromboprophylaxis in critical care
por: Helms, Julie, et al.
Publicado: (2022)

American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19
por: Cuker, Adam, et al.
Publicado: (2021)

Ongoing efforts to reduce perioperative morbidity of radical cystectomy: towards widespread adoption of extended-duration thromboprophylaxis
por: Packiam, Vignesh T., et al.
Publicado: (2018)

Unmet definitions in thromboprophylaxis for hospitalized medical patients: An appraisal for the need of recommendation
por: Ávila Ferreira, Bruno, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hl0s53roaatbg38t701uef5tsi